Correlation Between Lyra Therapeutics and Spyre Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyra Therapeutics and Spyre Therapeutics, you can compare the effects of market volatilities on Lyra Therapeutics and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Spyre Therapeutics.

Diversification Opportunities for Lyra Therapeutics and Spyre Therapeutics

0.21
  Correlation Coefficient

Modest diversification

The 3 months correlation between Lyra and Spyre is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Spyre Therapeutics

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Spyre Therapeutics. In addition to that, Lyra Therapeutics is 1.84 times more volatile than Spyre Therapeutics. It trades about -0.05 of its total potential returns per unit of risk. Spyre Therapeutics is currently generating about 0.05 per unit of volatility. If you would invest  2,660  in Spyre Therapeutics on September 3, 2024 and sell it today you would earn a total of  183.00  from holding Spyre Therapeutics or generate 6.88% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Lyra Therapeutics  vs.  Spyre Therapeutics

 Performance 
       Timeline  
Lyra Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Spyre Therapeutics 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Spyre Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Spyre Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Lyra Therapeutics and Spyre Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyra Therapeutics and Spyre Therapeutics

The main advantage of trading using opposite Lyra Therapeutics and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.
The idea behind Lyra Therapeutics and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital